Benjamin F. Edwards & Company’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-1,297
| Closed | -$238K | – | 1796 |
|
|
2021
Q2 | $238K | Sell |
1,297
-23
| -2% | -$3.95K | 0.01% | 610 |
|
|
2021
Q1 | $202K | Sell |
1,320
-63
| -5% | -$9.74K | 0.01% | 672 |
|
|
2020
Q4 | $216K | Sell |
1,383
-527
| -28% | -$67.7K | 0.01% | 621 |
|
|
2020
Q3 | $219K | Buy |
1,910
+183
| +11% | +$19.7K | 0.01% | 569 |
|
|
2020
Q2 | $194K | Sell |
1,727
-83
| -5% | -$8.81K | 0.01% | 583 |
|
|
2020
Q1 | $163K | Sell |
1,810
-1,039
| -36% | -$102K | 0.01% | 559 |
|
|
2019
Q4 | $308K | Buy |
2,849
+1,047
| +58% | +$112K | 0.02% | 499 |
|
|
2019
Q3 | $176K | Buy |
1,802
+902
| +100% | +$102K | 0.01% | 591 |
|
|
2019
Q2 | $118K | Hold |
900
| – | – | 0.01% | 662 |
|
|
2019
Q1 | $122K | Buy |
900
+200
| +29% | +$24.9K | 0.01% | 628 |
|
|
2018
Q4 | $68K | Buy |
+700
| New | +$82.7K | 0.01% | 759 |
|
|
2016
Q2 | – | Sell |
-83
| Closed | -$12K | – | 1144 |
|
|
2016
Q1 | $12K | Hold |
83
| – | – | ﹤0.01% | 779 |
|
|
2015
Q4 | $16K | Hold |
83
| – | – | ﹤0.01% | 747 |
|
|
2015
Q3 | $13K | Sell |
83
-36
| -30% | -$6.57K | ﹤0.01% | 819 |
|
|
2015
Q2 | $22K | Buy |
119
+55
| +86% | +$9.49K | ﹤0.01% | 764 |
|
|
2015
Q1 | $11K | Buy |
64
+41
| +178% | +$7.42K | ﹤0.01% | 882 |
|
|
2014
Q4 | $4K | Hold |
23
| – | – | ﹤0.01% | 925 |
|
|
2014
Q3 | $4K | Hold |
23
| – | – | ﹤0.01% | 891 |
|
|
2014
Q2 | $4K | Buy |
+23
| New | +$3.63K | ﹤0.01% | 849 |
|
Other funds holding ALXN
BCI
NICM
TAIM
RG
CFO
MAM